Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4442 Prevalence of second primary malignancies in patients with neuroendocrine tumours – Experience from a tertiary reference centre

Introduction: Neuroendocrine tumours (NETs) constitute a diverse group of tumours. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of OS.

Conference:

Presenting Author:

Authors: Komarnicki P, Woliński K, Maciejewski A, Musiałkiewicz J, Gut P,

Keywords: neuroendocrine neoplasm, neuroendocrine tumour, second primary malignancy, secondary malignancy, second primary neoplasm,

#4214 Splenic metastases in the course of neuroendocrine tumors – Are they really that uncommon?

Introduction: Splenic metastases are described as exceptional in the literature. Their frequency is low regardless of the type of neoplasm. In the course of neuroendocrine tumors (NETs), spleen involvement seems infrequent too. There is only a limited number of case reports of such presentation.

Conference:

Presenting Author:

Authors: Maciejewski A, Komarnicki P, Wietrzyk D, Musiałkiewicz J, Woliński K,

Keywords: NETs, metastases, spleen, clinical course,

#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1821 Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies

Introduction: LAN 120mg has been shown to significantly prolong progression-free survival (PFS) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Phan A

Authors: Phan A, Pavel M, Caplin M, Wolin E, Mirakhur B,

Keywords: lanreotide,

#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Phan A, Wolin E, Fisher G, Ruszniewski P, Pavel M,

Keywords: Lanreotide, safety,